Cambridge Healthtech Institute’s 2nd Annual

Emerging Indications for Therapeutic Antibodies
( 治疗用抗体的新适应症 )

R&D Advances in Non-Cancer Indications for Antibodies and Other Biotherapeutics



Significant scientific advances in the fields of immunology and protein science are driving the development of biotherapeutic drugs in a growing range of therapeutic areas beyond oncology. These advances are driving the identification of new and unique targets, new approaches to developing biotherapeutics for unserved medical needs, methods of binding to illusive targets and translational science for patient stratification and drug development for niche indications. The PEGS Emerging Indications for Therapeutic Antibodies conference provides a forum for research organizations with diverse portfolios to explore new science and technology in the development of a next generation of safe and effective therapeutics in an important set of emerging indications.

Coverage will include, but is not limited to:


Autoimmunity and Inflammation

  • Targeting regulatory T cells for autoimmune diseases
  • Using an “entry point” strategy to develop biotherapeutics against smaller indications in inflammatory and autoimmune diseases
  • Targeting complement pathways 


  • Update on clinical studies of antibody therapeutics for Alzheimer’s Disease
  • Antibodies against transmembrane GPCR and ion channel targets for pain
  • Anti-CGRP for migraine

Cardiovascular and Metabolic Diseases

  • Strategies for targeting metabolic diseases with antibodies and other biologics
  • The future prospects of PCSK9 and other lipid-lowering antibodies
  • Other CV indications: cardiovascular fibrosis, hemophilia

Rare Diseases

  • Strategies for genetic deficiencies
  • Antibodies and biologics as protein replacements
  • Translation of rare disease innovations to other therapeutic areas

Infectious Diseases

  • B-cell cloning and screening to identify new antibodies and understandings of adaptive immune response
  • Combining anti-viral and anti-bacterial agents
  • Anti-bacterial conjugates 

Other Indications

  • Regenerative medicine
  • Microbiota and antibody efficacy
  • Ophthalmology


* 活动内容有可能不事先告知作更动及调整。

Choose your language